Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target raised by research analysts at HC Wainwright from $23.00 to $30.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 66.67% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Chardan Capital upped their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Cantor Fitzgerald upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada lifted their price target on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eyepoint Pharmaceuticals currently has an average rating of “Buy” and an average target price of $31.50.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $18.00 on Thursday. Eyepoint Pharmaceuticals has a fifty-two week low of $3.91 and a fifty-two week high of $19.11. The company has a market capitalization of $1.49 billion, a PE ratio of -6.02 and a beta of 1.72. The stock has a fifty day moving average of $15.76 and a two-hundred day moving average of $14.31.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). The business had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. As a group, equities research analysts forecast that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $17.10, for a total value of $727,502.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.46% of the stock is owned by corporate insiders.

Institutional Trading of Eyepoint Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC acquired a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at $53,658,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth about $28,556,000. Orbimed Advisors LLC bought a new position in shares of Eyepoint Pharmaceuticals during the third quarter worth about $25,575,000. Suvretta Capital Management LLC grew its stake in Eyepoint Pharmaceuticals by 26.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock worth $143,012,000 after purchasing an additional 1,634,970 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company’s stock valued at $109,938,000 after buying an additional 1,601,101 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital raised its price target on EYPT to $29 and reiterated a “buy” rating, signaling institutional confidence and implying significant upside versus recent levels. Chardan Price Target Raise
• Positive Sentiment: Company reported >$300M cash & investments at 12/31/25 (runway into Q4 2027), appointed Michael Campbell as Chief Commercial Officer, and said both pivotal Phase 3 DURAVYU trials for wet AMD are on track — all items that improve launch readiness and reduce near‑term financing risk. Press Release
• Positive Sentiment: EyePoint reiterated a mid‑2026 topline data target for DURAVYU in wet AMD and DME as Phase 3 trials advance — a clear near‑term clinical catalyst that can materially re‑rate the stock if data are positive. Topline Timing Article
• Neutral Sentiment: Q4 earnings call transcripts and corporate presentation are available for details on commercial plans, cash runway and trial updates — useful for digging into management’s guidance and launch assumptions. Earnings Call Transcript (Seeking Alpha) Earnings Call Transcript (Yahoo)
• Neutral Sentiment: Short‑interest report posted anomalous/zero values (appears to be data/reporting noise); investors should treat reported large change with caution and check official exchange filings for accurate short interest. (No reliable link provided in the bulletin.)
• Negative Sentiment: Q4 results missed expectations: EyePoint reported a ($0.81) EPS vs. consensus ($0.78) and reported revenue of $0.62M (below some published expectations). The company still shows large negative margins and negative ROE, underscoring current unprofitability ahead of any commercial launch. Earnings Summary / Call Press Release / Financials
• Negative Sentiment: Analyst critique: a Seeking Alpha piece warns the “pre‑readout” rally may be masking commercial execution risks and realistic revenue ramp assumptions — a reminder that positive trial news must translate into durable commercial uptake to justify valuations. Commercial Reality Check

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.